top of page
News, Events and Updates
Search
Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Aug 2, 2022
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jul 31, 2022
Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release
Jun 20, 2022
Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD
Oct 13, 2021
Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits
Jul 28, 2021
Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Jun 13, 2021
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73
Jun 7, 2021
Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73
Jun 3, 2021
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board
Mar 30, 2021
Anavex Life Sciences Reports ANAVEX®2-73 featured as a Disease-Modifying Small Molecule in Trials
Mar 16, 2021
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 for Alzheimer’s
Aug 4, 2020
Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73
Jun 3, 2020
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
